Sareum Holdings
SAR · AIM · Health Care · mcap £38m · 27.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 08 Oct 26 | Capital Access Window - Sareum Holdings Plc
ORDINARY SHARES OF GBP 0.0125 EACH, FULLY PAID |
+0.0% | |
| 08 Oct 26 | Capital Access Window
Sareum enters Capital Access Window ahead of proposed equity fundraise to advance SDC-1801 programme. |
+0.0% | |
| 02 Sep 26 | Exercise of Warrants
Cambridge, UK, 2 September 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received noti |
+0.0% | |
| 19 Aug 26 | Exercise of Warrants
Cambridge, UK, 19 August 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notice |
−3.4% | |
| 07 Aug 26 | Exercise of Warrants
Cambridge, UK, 7 August 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices |
+0.0% | |
| 20 Jul 26 | Completion of Dosing in Toxicology Programme
Dosing completed in Phase 2-enabling toxicology programme for SDC-1801 on schedule. |
+4.2% | |
| 22 Jun 26 | Publication of Phase 1 data on SDC-1801 in BJCP
Phase 1 data on SDC-1801 published in peer-reviewed journal showing tolerability and target engagement. |
+7.0% | |
| 01 May 26 | Exercise of Warrants
Cambridge, UK, 1 May 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notice to |
−1.2% | |
| 12 Mar 26 | Results | Half-year Results
Half-Year Report for the Six Months Ended 31 December 2025 |
+7.1% |
| 17 Feb 26 | Restart of Phase 2-enabling toxicology programme
Restart of Phase 2-enabling toxicology programme for SDC-1801 |
−5.6% | |
| 09 Dec 25 | Result of AGM
Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AG |
+0.0% | |
| 09 Dec 25 | Annual General Meeting Statement
Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer publishes an update on operations and |
+0.0% | |
| 30 Oct 25 | Appointment of Joint Corporate Broker
Cambridge, UK, 30 October 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointme |
+0.0% | |
| 23 Oct 25 | Results | Final Results
Preliminary Results for the Year Ended 30 June 2025 |
+17.9% |
| 10 Oct 25 | Update on toxicology study for SDC-1801
Cambridge, UK, 10 October 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has discontinued i |
−22.1% |
Company filings. Not investment advice.